Quantcast
Last updated on April 24, 2014 at 12:48 EDT

Latest LEO Pharma A/S Stories

2013-03-19 08:27:07

BALLERUP, Denmark, March 19, 2013 /PRNewswire/ -- LEO Pharma announces a co-creation agreement with the National Psoriasis Foundation (NPF) in the United States that puts patients at the heart of LEO Pharma's innovation process. The move supports the dermatology company's aim to develop future care solutions that address patients' real-life needs. The co-creation agreement with the US National Psoriasis Foundation aims to ensure that the needs of people suffering from...

2013-03-18 08:30:00

MENLO PARK, California and BALLERUP, Denmark, March 18, 2013 /PRNewswire/ -- Virobay, Inc. and LEO Pharma A/S today announced that their collaboration on the development of an oral treatment for psoriasis has reached an important milestone as Virobay has now initiated a Phase 1 clinical trial of VBY-891 - a selective cathepsin S inhibitor. (Logo: http://photos.prnewswire.com/prnh/20130221/595427 ) The first Phase 1 trial of VBY-891 is a double-blind, randomized,...

2013-02-26 08:28:16

BALLERUP, Denmark and PLANEGG-MARTINSRIED, Germany, February 26, 2013 /PRNewswire/ -- LEO Pharma A/S, a global pharmaceutical company specialising in dermatology, has entered into an exclusive research and license agreement with the German biotech company 4SC Discovery GmbH with the primary aim of jointly researching, developing and commercialising an oral treatment for inflammatory skin diseases such as psoriasis. (Logo:...

2012-10-03 02:27:46

BALLERUP, Denmark, October 3, 2012 /PRNewswire/ -- LEO Pharma has announced plans to establish five long-term, strategic research collaborations in four countries by the end of next year. The ambitious initiative aims to deliver new treatment options to dermatology patients - faster than ever before. The first in the series of collaborations to be announced is with Charite, one of Europe's oldest and largest university hospitals. (Logo:...

2012-03-14 16:01:00

PARSIPPANY, New Jersey, March 14, 2012 /PRNewswire/ -- Ingenol mebutate was proven efficacious with a once-daily application for only 2 or 3 days Today, the New England Journal of Medicine (NEJM) published an analysis of pooled results from LEO Pharma's four Phase III clinical trials for ingenol mebutate gel, demonstrating that ingenol mebutate gel is safe and effective for the treatment of actinic keratoses (AKs) on the...

2012-01-09 06:00:00

BALLERUP, Denmark, January 9, 2012 /PRNewswire/ -- LEO Pharma A/S, a global pharmaceutical company specializing in dermatology, has entered into a multi-million dollar collaboration with the US biotech company Virobay Inc. to develop an oral treatment for psoriasis. (Logo: http://www.newscom.com/cgi-bin/prnh/20110606/460992 ) (Logo: http://www.newscom.com/cgi-bin/prnh/20120109/502540 ) The pharmaceutical company LEO Pharma A/S has signed an...

2011-02-25 06:00:00

DUBLIN, Feb. 25, 2011 /PRNewswire/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced its results for the quarter and year ended December 31, 2010. As discussed more fully below, our financial position and results of operations in the quarter ended December 31, 2010 as compared to the prior year quarter were significantly impacted by several important transactions in 2009 and 2010. These transactions included our acquisition of Novartis Pharmaceuticals Corporation's ("Novartis") U.S....

2010-11-08 06:00:00

DUBLIN, Nov. 8, 2010 /PRNewswire-FirstCall/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced its results for the quarter ended September 30, 2010. Revenue in the quarter ended September 30, 2010 increased 178.2% to $703.2 million over the prior year quarter. The primary drivers of the increase in revenue were the products acquired from The Procter & Gamble Company ("P&G"), primarily ACTONEL and ASACOL, which together contributed $448.4 million of revenue growth in the quarter...

2010-08-06 06:00:00

ARDEE, Ireland, Aug. 6 /PRNewswire-FirstCall/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced its results for the quarter ended June 30, 2010. Revenue in the quarter ending June 30, 2010 increased 225.2% to $815.6 million over the prior year quarter. The primary drivers of the increase in revenue were the products acquired from The Procter & Gamble Company ("P&G"), primarily ACTONEL, ASACOL and ENABLEX, which together contributed $477.4 million of revenue growth in the...

2010-05-07 06:00:00

ARDEE, Ireland, May 7 /PRNewswire-FirstCall/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced its results for the quarter ended March 31, 2010. Revenue in the quarter was $761.3 million, an increase of $515.3 million, or 209.5%, over the prior year quarter. The primary drivers of the increase in revenue were the products acquired from The Procter & Gamble Company ("P&G"), primarily ACTONEL, ASACOL and ENABLEX, which together contributed $445.5 million of revenue growth in the...